Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Common Equity (2016 - 2025)

Historic Common Equity for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $3.3 billion.

  • Neurocrine Biosciences' Common Equity rose 2561.69% to $3.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.3 billion, marking a year-over-year increase of 2561.69%. This contributed to the annual value of $3.3 billion for FY2025, which is 2561.69% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Common Equity stood at $3.3 billion, which was up 2561.69% from $3.0 billion recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Common Equity peaked at $3.3 billion during Q4 2025, and registered a low of $1.2 billion during Q1 2021.
  • Over the past 4 years, Neurocrine Biosciences' median Common Equity value was $2.4 billion (recorded in 2024), while the average stood at $2.2 billion.
  • As far as peak fluctuations go, Neurocrine Biosciences' Common Equity soared by 7215.48% in 2021, and later soared by 626.96% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Common Equity stood at $1.3 billion in 2021, then skyrocketed by 65.82% to $2.2 billion in 2023, then grew by 16.03% to $2.6 billion in 2024, then increased by 25.62% to $3.3 billion in 2025.
  • Its Common Equity stands at $3.3 billion for Q4 2025, versus $3.0 billion for Q3 2025 and $2.7 billion for Q2 2025.